This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|April 4, 2019
ITT Showcases Hygienic Valve Technology at INTERPHEX 2019
Author(s)BioPharm International Editors
ITT Engineered Valves presented its new EnviZion hygienic valve technology at INTERPHEX 2019 in New York City.
Advertisement
ITT Engineered Valves, a manufacturer of industrial and hygienic valves for chemical processing, power generation, pulp and paper, mining, pharmaceutical, and bioprocessing, showcased its EnviZion hygienic valve technology for biopharmaceutical operations at INTERPHEX at the Jacob K. Javits Convention Center in New York City, taking place April 2–4, 2019.
Company representatives at booth 3644 demonstrated how the valve’s design and engineering can improve performance and reliability. According to the company, the valve has received in-house testing as well as independent third-party testing from American Society of Mechanical Engineers: Bioprocessing Equipment Appendix J and certification from the European Hygienic Engineering and Design Group.
The demonstrated was divided into reliability and profitability stations. At the reliability station, visitors could change a diaphragm on a traditional four-bolt valve and on the EnviZion valve to experience the operational and maintenance differences first-hand. At the profitability station, visitors could consult with a company team member to evaluate how the EnviZion valve technology translates to installation, operation, and maintenance savings.
Additionally, other product stations highlighted several new EnviZion products, including the BioviZion fractional size valve and the Advantage platform of pneumatic actuators.
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5